<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03414541</url>
  </required_header>
  <id_info>
    <org_study_id>DS102A-03</org_study_id>
    <nct_id>NCT03414541</nct_id>
  </id_info>
  <brief_title>Safety And Efficacy Study Of Orally Administered DS102 In Patients With Chronic Obstructive Pulmonary Disease</brief_title>
  <official_title>A Randomised, Double-Blind, Placebo-Controlled, Exploratory Phase IIa Study To Assess The Safety And Efficacy Of Orally Administered DS102 In Chronic Obstructive Pulmonary Disease Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Afimmune</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Afimmune</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this randomised, double-blind, placebo-controlled, parallel group study is to
      assess the safety and efficacy of orally administered DS102 capsules versus placebo in the
      treatment of adult patients with Chronic Obstructive Pulmonary Disease (COPD).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 24, 2017</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in induced sputum differential neutrophil count from baseline to Week 12</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Treatment Emergent Adverse Events (TEAEs) in each treatment group leading to treatment discontinuation.</measure>
    <time_frame>12 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in induced sputum neutrophil differential count from baseline</measure>
    <time_frame>14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in St Georges Respiratory Questionnaire (SGRQ) from baseline</measure>
    <time_frame>14 weeks</time_frame>
    <description>Questionnaire designed to measure impact of COPD on overall health, daily life and perceived well-being. Scores range from 0 -100 with higher scores indicating more limitations.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants in this group will receive matching placebo capsules twice daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>500mg DS102</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this group will receive 500 mg DS102 capsules twice daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1000mg DS102</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this group will receive 1000 mg DS102 capsules twice daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DS102</intervention_name>
    <description>DS102</description>
    <arm_group_label>500mg DS102</arm_group_label>
    <arm_group_label>1000mg DS102</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients (male or female) aged 40-75 years with stable COPD at the time of screening.

          -  Patients who are current or ex-smokers who have a smoking history of at least 10 pack
             years (Ten pack- years are defined as 20 cigarettes a Day for 10 years, or 10
             cigarettes a Day for 20 years).

          -  Patients whose pre-study clinical laboratory findings do not interfere with their
             participation in the study, in the opinion of the Investigator.

          -  Patients who are able to communicate well with the Investigator, to understand and
             comply with the requirements of the study, and understand and sign the written
             informed consent.

        Exclusion Criteria:

          -  Patients with a history of malignancy of any organ system (including lung cancer),
             treated or untreated, within the past 5 years whether or not there is evidence of
             local recurrence or metastases, with the exception of localized basal cell carcinoma
             of the skin.

          -  Patients with significant systemic or major illness other than pulmonary disease,
             including coronary artery disease, liver disease, cerebrovascular disease, renal
             insufficiency, serious psychiatric disease, respiratory or hypertensive disease, as
             well as diabetes and arthritis that, in the opinion of the Investigator, would
             preclude the patient from participating in and completing the study.

          -  Patients with known hypersensitivity to any ingredients of the study treatment.

          -  Patients, in the opinion of the Investigator, not suitable to participate in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Karen Doyle</last_name>
    <phone>00 353 1 2946385</phone>
    <email>karen.doyle@afimmune.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Manchester Evaluations Unit (MEU)</name>
      <address>
        <city>Manchester</city>
        <state>Wythenshawe</state>
        <zip>M23 9QZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dave Singh</last_name>
      <email>dsingh@meu.org.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Celerion</name>
      <address>
        <city>Belfast</city>
        <zip>BT9 6AD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abou Farha Khalid</last_name>
      <email>khalid.aboufarha@celerion.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 23, 2018</study_first_submitted>
  <study_first_submitted_qc>January 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 30, 2018</study_first_posted>
  <last_update_submitted>February 1, 2018</last_update_submitted>
  <last_update_submitted_qc>February 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

